STAT

Opinion: PhRMA’s talking points shouldn’t derail the Pelosi drug pricing bill

We need serious reform of both pricing and insurance coverage of prescription drugs. There will be tradeoffs, but if you want to know what they are, don't read PhRMA's talking…
Roche's Building 1 tower under construction on the banks of the Rhine river in Basel in 2014.

Two of the most innovative pharmaceutical corporations in the world have their headquarters on opposite banks of the Rhine as it flows through Basel, Switzerland. Ranked No. 2 and 4 in total worldwide sales, Roche makes Herceptin and other important cancer treatments while Novartis recently brought to market the immune therapy Kymriah and the gene therapy Zolgensma. Sanofi (7) is in Paris, Glaxo Smith Kline (6) and AstraZeneca (14) are in London, and Takeda (20) is based in

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks